Current Trials

ACTIVELY ENROLLING STUDIES

ONCOLOGY

BREAST

S1703 - (opened 4/2019): Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer.

NRG-BR007 DEBRA - (opened 8/2021): A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2- Negative, Oncotype Recurrence Score.

A012303 ShortStop - (opened 1/2026): ShortStop- HER2: Shortened Duration Of Adjuvant Therapy In Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

EA1241 - (opened 2/2026): Extended Clinical Follow Up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol

GI

NRG-GI008 - (opened 1/2026): Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

A022102 - (opened 2/2026): A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

S2433 - (opened 2/2026): Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

GENETICS

GH-101 - (opened 3/2025): Genetic Susceptibility and Management of Chronic Disease

For More Information:

If you would like additional information about the Center for Research, please send your name, company or practice name, address and telephone number to the following address:

Watson Clinic Center for Research

1600 Lakeland Hills Blvd

Lakeland, FL 33805

Attn: Center for Research Director

Phone 863-688-6826 · FAX 863-688-5842

Please indicate which of the following type(s) of information you would like: